$2.78
7.19% today
Nasdaq, Sep 25, 07:47 pm CET
ISIN
US38341P1021
Symbol
GOSS

Gossamer Bio, Inc. Stock price

$2.99
+0.63 26.69% 1M
+1.71 133.59% 6M
+2.09 230.53% YTD
+2.00 200.84% 1Y
-9.06 75.19% 3Y
-8.57 74.13% 5Y
-13.71 82.10% 10Y
-13.71 82.10% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.09 2.92%
ISIN
US38341P1021
Symbol
GOSS
Industry

Key metrics

Basic
Market capitalization
$679.9m
Enterprise Value
$665.0m
Net debt
positive
Cash
$212.9m
Shares outstanding
227.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.9 | 18.1
EV/Sales
16.5 | 17.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
9.4%
Return on Equity
-191.7%
ROCE
-77.7%
ROIC
-5,338.2%
Debt/Equity
-4.3
Financials (TTM | estimate)
Revenue
$40.2m | $37.5m
EBITDA
$-141.4m | $-146.3m
EBIT
$-145.6m | $-161.0m
Net Income
$-138.7m | $-154.8m
Free Cash Flow
$-154.4m
Growth (TTM | estimate)
Revenue
-58.0% | -67.3%
EBITDA
-107.4% | -162.4%
EBIT
-109.9% | -168.6%
Net Income
-71.6% | -173.9%
Free Cash Flow
-3,889.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-351.5% | -390.6%
EBIT
-361.9%
Net
-344.8% | -413.3%
Free Cash Flow
-383.7%
More
EPS
$-0.6
FCF per Share
$-0.7
Short interest
10.3%
Employees
145
Rev per Employee
$790.0k
Show more

Is Gossamer Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Gossamer Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Gossamer Bio, Inc. forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Gossamer Bio, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Gossamer Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
40 40
58% 58%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
4% 4%
88%
- Research and Development Expense 151 151
17% 17%
374%
-141 -141
107% 107%
-351%
- Depreciation and Amortization 4.20 4.20
253% 253%
10%
EBIT (Operating Income) EBIT -146 -146
110% 110%
-362%
Net Profit -139 -139
72% 72%
-345%

In millions USD.

Don't miss a Thing! We will send you all news about Gossamer Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gossamer Bio, Inc. Stock News

Neutral
PRNewsWire
about 7 hours ago
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (...
Neutral
Business Wire
about 7 hours ago
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respir...
Neutral
Business Wire
3 days ago
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will ...
More Gossamer Bio, Inc. News

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Faheem Hasnain
Employees 145
Founded 2015
Website www.gossamerbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today